Loading clinical trials...
Loading clinical trials...
Single-center, Randomized, Double-blind, Placebo-controlled, Sequential Cohort Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAD of FXI-GalNAc-siRNA When Administered Subcutaneously to Healthy Subjects.
Conditions
Interventions
FXI-GalNAc-siRNA
Placebo
Locations
2
United States
BioPharma
Creve Coeur, Missouri, United States
BioPharma
Toronto, Ontario, Canada
Start Date
May 16, 2023
Primary Completion Date
May 1, 2024
Completion Date
June 1, 2024
Last Updated
March 18, 2024
NCT00713648
NCT01847989
NCT01253811
Lead Sponsor
Sirnaomics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions